Enanta Pharmaceuticals, Inc. Forecast, price target & analysts
Enanta Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Enanta Pharmaceuticals, Inc. Classifications & Recommendation:
Enanta Pharmaceuticals, Inc. Price Target
| Target Price | $20.40 |
| Price | $14.09 |
| Potential |
44.78%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Enanta Pharmaceuticals, Inc. 2026 .
The average Enanta Pharmaceuticals, Inc. target price is $20.40.
This is
44.78%
register free of charge
$29.40
108.66%
register free of charge
$9.09
35.49%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend Enanta Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Enanta Pharmaceuticals, Inc. stock has an average upside potential 2026 of
44.78%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 65.32 | 66.72 |
| 3.43% | 2.14% | |
| Net Margin | -125.37% | -108.27% |
| 26.93% | 13.64% |
8 Analysts have issued a sales forecast Enanta Pharmaceuticals, Inc. 2026 . The average Enanta Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Enanta Pharmaceuticals, Inc. EBITDA forecast 2026. The average Enanta Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2027 |
$-105m
6.19%
Unlock
|
|
|---|---|---|
EBITDA Margin
| 2027 |
-153.27%
3.35%
Unlock
|
|
|---|---|---|
9 Enanta Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Enanta Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Sep '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.84 | -3.38 |
| 30.05% | 11.98% | |
| P/E | negative | |
| EV/Sales | 3.35 |
9 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast for earnings per share. The average Enanta Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Enanta Pharmaceuticals, Inc....
Current Enanta Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 14 2025 |
| WestPark Capital |
Locked
➜
Locked
|
Locked | Sep 30 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
| WestPark Capital |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 14 2025 |
|
Locked
WestPark Capital:
Locked
➜
Locked
|
Sep 30 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Sep 15 2025 |
|
Locked
WestPark Capital:
Locked
➜
Locked
|
Sep 02 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Jun 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 11 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
